StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-07 | $1.15 | $1.14 | -0.87% | 0.1M |
| 05-08 | $1.15 | $1.07 | -6.96% | 0.3M |
| 05-11 | $1.09 | $1.08 | -0.92% | 0.2M |
| 05-12 | $1.11 | $1.10 | -0.90% | 0.2M |
| 05-13 | $1.12 | $1.13 | +0.89% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
| Metric | Annual 2020 2020-12-31 | Q3 2020 2020-09-30 | Q2 2020 2020-06-30 | Q1 2020 2020-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-8.79M | $-6.33M | $-4.03M | $-2.36M |
Net Income | $-8.79M | $-6.33M | $-1.67M | $-2.35M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $15.74M | $18.24M | $20.21M | $14.30M |
Total Liabilities | $2.72M | $2.79M | $2.48M | $2.32M |
Cash & Equivalents | $14.29M | $16.92M | $18.91M | $13.33M |
Free Cash Flow OCF − CapEx | $-8.82M | $-6.20M | $-4.22M | $-2.19M |
Shares Outstanding | 5.78M | 5.78M | 5.78M | 2.87M |
No sell-side coverage available for PHIO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for PHIO.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.